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ABSTRACT
Introduction: Mucopolysaccharidosis type II (MPSII) is an X-linked lysosomal disorder 
caused by deficiency of iduronate-2-sulfatase (IDS). In this study, we proposed a new 
protocol for prenatal diagnosis, using DNA obtained from amniotic fluid cells that did 
not attach to the bottom of the culture flask after the first medium change.
Methods: Four pregnant MPS II carriers were referred to the Medical Genetics Service 
of Hospital de Clinicas de Porto Alegre for a prenatal diagnosis and identification of 
the disease, which were performed by polymerase chain reaction (PCR) amplification, 
restriction fragment length polymorphism, and sequencing according to the mutation 
previously found in the family.
Results: The analysis indicated the absence of mutation in three fetal materials and 
the presence of mutation in one case. Concomitantly, cytogenetic and biochemical 
analyses were performed after 12 days of cell culture, and only one case showed 
absence of enzyme activity, confirming the molecular analysis.
Conclusions: This diagnostic protocol designed to provide more robust results and 
safer genetic counseling suggests that DNA obtained from floating amniotic fluid cells 
can be used as a source of fetal material to allow a faster alternative for prenatal 
care through molecular analysis. Determination of IDS gene mutation in fetal amniotic 
fluid cells together with IDS enzyme activity testing is a rapid, sensitive and accurate 
method for prenatal diagnosis of MPS II for high-risk pregnant women.
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Mucopolysaccharidosis type II (MPS II) or Hunter disease, the most 
frequently diagnosed MPS in Brazil1, is a lysosomal disorder caused by 
deficiency of iduronate-2-sulfatase (IDS), which is involved in the catabolism of 
glycosaminoglycans dermatan and heparn sulfate2. Estimates of the incidence 
for this disease range from 1:68,000 to 1:320,000 live births.
Considering that MPS II is an X-linked disease, the risk to siblings depends 
on the carrier status of the mother. For example, if she has the disease-causing 
mutation in one of her X chromosomes, the chance of transmitting it in each 
pregnancy is 50%, and males who inherit the mutation will be affected2. 
Females carrying a mutation in one IDS allele are usually asymptomatic1.
Enzyme activity cannot be used to identify female carriers because, 
although IDS activity in female carriers is on average about 50% of that seen 
in non-affected individuals, considerable overlap is observed3.
Prenatal diagnosis has become a major aid to genetic counseling and have 
been improved by advances in several important areas, such as cytogenetics, 
biochemistry, and molecular biology. The identification of the IDS mutation 
in an index case is needed to confirm carrier status and is very important for 
prenatal diagnosis and genetic counseling in MPSII.
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Laboratory prenatal assays, including fetal sex 
determination, measurement of enzyme activity, 
and mutation analysis, depend on cultured cells 
harvested from amniotic fluid, obtained at mid-
trimester amniocentesis.
We proposed here a new protocol for mutation 
analysis and prenatal diagnosis of MPS II using free 
amniotic fluid cells present in the supernatant that 
did not attach to the bottom of the tissue culture flask 
after the first medium change.
METHODS
The Molecular Genetics Laboratory of the Medical 
Genetics Service of Hospital de Clínicas de Porto 
Alegre, Brazil, is a reference center for MPS diagnosis 
and receives samples from all over Brazil4. The 
present study included four MPS II pregnant carriers 
who were referred for prenatal analysis around 15-16 
weeks of gestational age. They all had a previous 
child with MPS II disease who was diagnosed by 
the presence of dermatan and heparan sulfate 
and high concentration of glycosaminoglycans in 
urine, in addition to low activity of IDS in leukocytes 
(excluding multiple sulfatase deficiency by another 
sulfatase measurement) and molecular analysis 
that identified a hemizygous individual for a specific 
mutation in the IDS gene after sequencing. The 
dimethylmethylene blue (DMB) method5 was used 
for glycosaminoglycans quantification, and IDS was 
measured using a fluorogenic method6.
Only pregnant women who were known to carry 
a male fetus, as seen by echography examination 
or fetal sex determination by DNA analysis, were 
referred for MPSII diagnosis.
An informed consent was obtained by the physician 
before diagnostic testing. Amniotic fluid was collected 
at mid-trimester amniocentesis, and the cells were 
grown for 12 days. Measurement of enzyme activity 
and cytogenetic analysis were performed for the four 
pregnant women at high risk for MPS II. Meanwhile, 
genomic DNA was extracted from the “floating cells” 
after 5 days of cell culture with the Invisorb Spin 
Micro DNA kit (Invitek) and was used as a template 
for PCR synthesis of IDS-specific amplicons using 
previously described primers7.
The exons to be amplified were chosen according to 
previous mutation analysis in the family. Sequencing of 
IDS genomic amplicons was subsequently performed 
using ABI Prism 3500 DNA sequencer (Applied 
Biosystems) according to the protocol provided by 
the manufacturer.
RESULTS
Enzyme activity assays showed normal rates 
(reference values: 50 to 100 nmol/h/mg prot) of IDS 
activity in amniotic fluid cells for cases 1 and 3 and 
undetectable activity for case 2 (table 1). IDS gene 
sequencing showed normal male fetus in cases 1, 
3 and 4 and hemizygous for the family mutation in 
case 2, confirming the biochemical findings (table 1).
Biochemical analysis could not be performed in 
one case (case 4), because the amount of material 
derived from the cell culture was not sufficient to 
achieve a final result. However, we were able to 
exclude the possibility that the fetus was a carrier 
of Hunter syndrome by mutation analysis.
DISCUSSION
During the cell culture procedures, we observed 
a considerable number of floating cells after the first 
medium change. These cells are usually discarded; 
nevertheless, they can be a good source of a 
considerable amount of DNA for further molecular 
analysis. Thus, we proposed and developed a 
protocol for DNA extraction from these cells in order 
to guarantee a prenatal laboratory result regardless 
of whether cell culture was successful or not, and 
also to abbreviate the molecular results in cases of 
known mutation within the family.
Determination of IDS gene mutation in fetal 
amniotic fluid cells together with IDS enzyme activity 
testing is a rapid, sensitive and accurate method for 
prenatal diagnosis of MPS II in high-risk pregnancies.
Prenatal analysis can be very important for early 
treatment of severe and progressive diseases by 
enzyme replacement therapy, bringing new perspectives 
for patients and families.
Table 1: Molecular, biochemical and cytogenetic results.
Case 1 Case 2 Case 3 Case 4
Mother’s age 27 years old 36 years old 36 years old 33 years old
Mutation* Absence (p.D45G) Presence (p.P231L) Absence (p.R468W) Absence (p.H335R)






* Mutation found previously in the index case. ** Culture failure.
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The identification of the gene defect is not 
required for MPS II diagnosis but can be helpful 
for phenotype prediction and for the identification 
of carriers. Carriers frequently exhibit an enzyme 
activity in between the ranges of affected patients 
and normal controls, but some overlap is usually 
observed; therefore, enzyme activity levels cannot 
be used alone to predict carrier status3.
MPS II shows wide allelic and phenotypic 
heterogeneity4. Patients are usually classified as 
having the severe or attenuated forms, depending 
mainly on the degree of mental retardation2,3. In 
general, it seems that patients with the more severe 
forms are diagnosed earlier, have mental retardation 
that is evident by the age of 4-6 years, and are 
dead by the age of 10-15 years, while patients with 
the attenuated forms have normal intelligence2,8,9. 
However, as there is no standardized scoring index 
of severity for MPS II, this classification is not always 
reliable, especially in the case of patients diagnosed 
during childhood9.
The cases presented here illustrate the importance 
of a comprehensive prenatal diagnostic protocol 
to provide more robust results and safer genetic 
counseling.
A molecular approach was incorporated into our 
prenatal routine in order to obtain a rapid diagnosis 
and allow for sex determination and mutation 
detection within a few days after biological samples 
were collected, decreasing the time for final report.
This protocol using free amniotic fluid cells can 
be used for many other diseases that can benefit 
from molecular diagnosis for definition of the fetus 
status even in the event of a culture failure. Taking 
into account the advent of next generation sequencing 
for molecular diagnosis on minimum amounts of 
biological material, this approach would be highly 
recommended.
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